Depo-Provera Lawsuits: What Changed From 2025 to 2026

Last updated: October 2026

Depo-Provera lawsuits changed a lot between 2025 and 2026. On the regulation side, the FDA approved a U.S. meningioma warning in December 2025 after rejecting one in 2024. On the legal side, the federal cases grew into one of the larger drug MDLs and reached a signed, confidential settlement agreement in July 2026. Advocates and clinicians, meanwhile, pushed for clearer warnings while stressing that the shot remains an important birth control option. We also explain how to rebuild your injection history, what a meningioma diagnosis means and how Depo-Provera lawsuits work for one person after the settlement.

This post looks at those three areas side by side: regulation, advocacy and the legal landscape. For a deeper look at the case itself, see our MDL 3140 explainer.

Regulation: from rejection to a U.S. warning

The biggest regulatory shift was the FDA’s reversal. In 2024, the FDA rejected Pfizer’s request to add a meningioma warning to Depo-Provera. The agency said observational studies alone did not support it, according to NBC News.

That same year, regulators in Europe and Canada added meningioma warnings. For a while, U.S. patients had less warning than patients abroad.

In December 2025, the FDA approved a label change adding meningioma risk to Depo-Provera and a related lower-dose product. According to a drug safety summary, the label tells prescribers to watch for signs such as:

• Headaches
• Vision changes
• Hearing loss or ringing in the ears
• Seizures

It also says the drug should be stopped if a meningioma is diagnosed. The shot remains FDA-approved.

The science kept developing

The 2024 French study in the BMJ was the spark. It linked use of injectable medroxyprogesterone acetate for a year or more to about 5.6 times higher odds of meningioma surgery.

New research continued in 2026. A large Danish study in JAMA Network Open, reported by Pharmacy Times in July 2026, looked at about 3 million women. It found injectable DMPA had the strongest link to meningioma among the progestogens studied. It also reported that risk appeared to decline in the years after stopping.

Both studies stress one point: the absolute risk for any one person is low. The findings show a link, not proof that the shot caused any one woman’s tumor.

Advocacy: warnings and access

Advocacy around Depo-Provera has pulled in two directions, and both matter.

Pushing for clearer warnings

Patients and their lawyers argued that U.S. women deserved the same warnings given in other countries. When the FDA acted, plaintiffs’ co-lead counsel said they “applaud the FDA in finally requiring this label change,” according to Pharmaceutical Technology.

Many women also shared that they learned of the possible link only after a diagnosis. That experience helped drive awareness and new filings.

Protecting birth control choices

Reproductive health groups have urged balance. The Reproductive Health Access Project, in a February 2026 clinical note, encouraged shared decision-making. It pointed out benefits of the shot, such as less painful periods, and said the risk to any one person is low.

The takeaway for patients is simple. Do not stop or switch birth control on your own because of headlines. Talk with a clinician about your history and options.

The legal landscape: how the cases changed

2025: building the MDL

In February 2025, the Judicial Panel on Multidistrict Litigation centralized the federal cases in the Northern District of Florida. Judge M. Casey Rodgers set strict early rules requiring proof of use and injury.

Pfizer’s main defense is preemption. It argues federal law blocks the claims because the FDA rejected a warning in 2024. The court heard arguments in 2025, then asked for more briefing after the FDA approved the warning.

2026: from growth to settlement

The case grew fast. The court reported 6,289 total actions as of late July 2026, in Case Management Order No. 12.

In June 2026, Pfizer said it had reached an agreement in principle with plaintiff leadership, according to legal news reports. The company said the deal includes no admission of liability. The court’s July order then confirmed that a Master Settlement Agreement was signed on July 21, 2026.

According to that order:

• The deal is private and confidential; no amounts have been released.
• It covers a majority of claims in the MDL and in New York state court.
• About 80% of current MDL plaintiffs are expected to be eligible.
• The court will still rule on preemption and the science for cases outside the deal.

The court has since appointed a settlement administrator and other administrators. Its MDL page lists the next case management conference for December 18, 2026.

State courts

State cases have their own path. The court’s July 2026 order listed cases in Delaware, New York, California, Minnesota and other states. In California, cases are coordinated in Alameda County Superior Court, which the Daily Journal reported in September 2026 is still moving forward.

What has not changed

With so much news, it helps to know what stayed the same. Some basic facts about these cases have held steady since 2025.

• Each claim is individual. An MDL is not a class action. Each person’s records, diagnosis and treatment still matter.
• Proof still matters. The court has required proof of Depo-Provera use and proof of a meningioma diagnosis from the start.
• Pfizer denies wrongdoing. The company says it stands behind the drug and that the settlement is not an admission of liability.
• Deadlines still apply. State filing deadlines still apply, and they vary by state and claim type. Do not assume the settlement stops the clock for you; ask an attorney.

Knowing this can help you sort real updates from noise. If a website claims a change that no court order supports, treat it with caution.

What these changes mean for you

If you used Depo-Provera, these shifts may affect you in practical ways:

• If you use it now: Talk with your clinician about the new warning and your options.
• If you have symptoms: Our post on meningioma symptoms that warrant an MRI explains when to speak up.
• If you have a diagnosis: You may want a review of your records to see where you fit in the settlement or the ongoing litigation.

Filing deadlines vary by state and claim type. Some start when you learn of your injury, so waiting can limit your options.

Building your injection history for Depo-Provera lawsuits

One thing that has not changed is the need for proof. Courts handling Depo-Provera lawsuits have asked for records of use from the start. If you received the shot years ago, finding those records may take some effort, but it is often possible.

How often the shot was given

The FDA-approved label says the usual dose of Depo-Provera CI is one injection every 3 months, or 13 weeks. That means a person who used the shot for several years may have had many separate visits. Each visit can leave a record. You can see the dosing and the meningioma warning in the FDA prescribing information.

Places to look for records

• Your doctor’s office or women’s health clinic. Visit notes and medication records often list each injection.
• Family planning and community health clinics. Many people received the shot at public or nonprofit clinics.
• School or college health centers. Some people started the shot as students.
• Pharmacies. If you picked up the shot to bring to your appointment, pharmacy records may show each fill.
• Your health insurer. Claims history and explanation of benefits statements can show dates and billing codes.
• Military or VA health records. If you served, your service medical records may list injections.

Brand name or generic?

Some people received the Pfizer brand, while others received a generic version of medroxyprogesterone acetate. Records may list either name. Write down exactly what your records show, including any lot numbers or product names, and ask a participating law firm whether it matters for how Depo-Provera lawsuits may apply to you.

If records are missing

Clinics close, merge or move old files to storage. If a provider cannot find your records, ask whether another health system took over its patients. Insurance claims and pharmacy histories can sometimes fill the gaps. Missing records do not always rule out a claim, and a firm that reviews Depo-Provera lawsuits can often request records for you with your signed permission.

Build a simple timeline

List the years you used the shot, where you received it and about how many injections you had. Add the date of any meningioma symptoms, imaging and diagnosis. A clear one-page timeline can make a records review much faster. It also helps you give the same answers each time a firm or court form asks about your history in Depo-Provera lawsuits.

Understanding a meningioma diagnosis

Many people first hear the word “meningioma” after a scan, often before they have heard of Depo-Provera lawsuits at all. Knowing the basics can help you talk with your doctors and understand your records.

What a meningioma is

The National Cancer Institute (NCI) explains that a meningioma is a tumor that forms in the meninges, the layers of tissue that cover the brain and spinal cord. NCI says meningiomas are the most common type of primary brain tumor. You can read more on the NCI meningioma page.

Grades

NCI describes three grades:

• Grade 1: low grade and slow growing. This is the most common type.
• Grade 2 (atypical): mid grade, with a higher chance of coming back after treatment.
• Grade 3 (anaplastic): high grade and fast growing. This type is rare.

Symptoms and tests

According to NCI, symptoms depend on where the tumor is. They can include vision changes, hearing or smell loss, confusion, seizures and headaches in the morning. MRI scans are commonly used to find meningiomas, and a tissue sample checked by a neuropathologist can confirm the diagnosis.

Records to keep

• MRI and CT reports, including the date of your first scan
• Notes from your neurologist or neurosurgeon
• Pathology reports, if you had surgery or a biopsy
• Radiation therapy records, if you received treatment
• Follow-up scan reports showing changes over time

These records matter for your care first. They are also the kind of proof that Depo-Provera lawsuits rely on to confirm a diagnosis.

Why timing matters

The dates in your records can matter a great deal. The label notes that meningioma cases have been reported mainly with long-term use. Firms reviewing Depo-Provera lawsuits often look at how long you used the shot and when your symptoms and diagnosis came after that. Accurate dates help them see where you may fit.

Questions to ask your doctor

• What grade is my meningioma, and where is it located?
• What are my treatment options, and what are the risks of each one?
• How often will I need follow-up scans?
• Should I stop or change my birth control, and what other options do I have?

Never stop or switch birth control on your own. Your clinician can help you choose a safe option that fits your health history.

How Depo-Provera lawsuits work for one person

News about a settlement can make it sound like everything is settled. In reality, each person in Depo-Provera lawsuits still has their own claim, their own records and their own choices. This section explains, in general terms, what that can look like.

If you have already filed

If you are already part of Depo-Provera lawsuits in the MDL or a state court, your law firm will explain whether you are expected to be eligible for the settlement program and what steps come next. Settlement programs often involve claim forms, records review and deadlines set by an administrator. Read every letter from your firm, and ask questions if something is unclear. It is fine to ask a trusted family member to help you keep track of forms and dates.

If you have not filed yet

If you have a meningioma diagnosis and used the shot, you can still ask a participating law firm to review your records. The firm can explain whether new claims may fit into the existing agreement, the ongoing litigation or a state court case. Filing deadlines vary by state and claim type, and a settlement does not pause them for everyone.

If you are outside the deal

The court’s July 2026 order said it would still rule on preemption and the science for cases outside the settlement. That means some Depo-Provera lawsuits may keep moving through the courts on a separate path. Your firm can explain what that may mean for your timeline.

Watch for misleading claims

As Depo-Provera lawsuits have grown, so have ads and websites about them. Be careful with any source that promises a set payout, claims to know the confidential settlement amounts or pressures you to sign up right away. Check updates against court orders or ask a participating law firm.

Stay reachable

Settlement programs and court cases can move in stages, and some steps have short deadlines. Tell your firm if you move or change your phone number or email. Keep every letter in one folder so nothing about your place in Depo-Provera lawsuits gets missed.

Questions to ask a participating law firm

• Am I likely to be eligible for the settlement program, and how will I know?
• Which deadline may apply in my state?
• What records do you need, and can you request them for me?
• How will you explain your fees and costs in writing?
• How often will you update me on my claim?

Glossary of terms used in Depo-Provera lawsuits

Legal and medical papers in these cases use many unfamiliar words. Here are plain definitions to help you follow updates about Depo-Provera lawsuits.

• Depo-Provera CI: an injectable birth control shot given about every 3 months.
• Medroxyprogesterone acetate (MPA or DMPA): the hormone in the shot. It is a man-made form of progesterone, called a progestin.
• Meningioma: a tumor that forms in the layers of tissue covering the brain and spinal cord.
• Neurosurgeon: a surgeon who operates on the brain and spine.
• Craniotomy: surgery in which part of the skull is opened to reach the brain.
• MRI: an imaging test that uses magnets and radio waves to make detailed pictures of the brain.
• Label change: an update to a drug’s official prescribing information, such as the December 2025 meningioma warning.
• Preemption: Pfizer’s main defense, the argument that federal law blocks certain state-law claims.
• MDL 3140: the federal multidistrict litigation for Depo-Provera cases in the Northern District of Florida.
• Master Settlement Agreement: the agreement signed in July 2026 to resolve many claims. Its terms are confidential.
• Settlement administrator: the company appointed to manage claims in a settlement program.
• Case Management Order (CMO): a court order that sets rules and schedules for the cases.
• Statute of limitations: the deadline to file a case. It varies by state and claim type.

Knowing these terms can help you separate real updates from rumors and ask clear questions about where you stand in Depo-Provera lawsuits.

Depo-Provera lawsuits: frequently asked questions

How Direct2Attorney can help

Depo-Provera lawsuits have changed quickly, from a new MDL to a U.S. warning to a signed settlement. If you were diagnosed with a meningioma after using the shot, Direct2Attorney can connect you with a participating law firm that may review your records. Learn more on our Depo-Provera lawsuit page.

Direct2Attorney is a legal marketing and referral service, not a law firm. This article is general information, not legal advice. Submitting information does not create an attorney-client relationship.